Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though ...

That brings us to Amgen. In November, it reported mid-stage clinical trial results for MariTide, an investigational weight loss treatment, and the market responded by sending the stock down more ...

TERN-601 showed modest weight loss results but falls short compared to competitors like semaglutide and Amgen's MariTide. With a market cap of $383mn and trading at cash, Terns' strategy of ...

Amgen's shares fell late last year after it released phase 2 data for its weight loss candidate, MariTide. Though the stock has rebounded somewhat, it's still down over the past year. MariTide's ...